Dianthus Therapeutics Achieves Early GO Decision in Pivotal Phase 3 CIDP Trial for Claseprubart
Summary
Dianthus Therapeutics announced an early "GO decision" in its Phase 3 CAPTIVATE trial for claseprubart in CIDP, indicating strong efficacy and safety, and plans to streamline the trial design, further de-risking its lead asset.
Key Events
-
Early Phase 3 GO Decision
Dianthus achieved an early "GO decision" in its Phase 3 CAPTIVATE trial for claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), meeting success criteria ahead of Q2'26 guidance.
-
Positive Interim Data & Safety Profile
The decision was based on 20 confirmed responders achieved with less than 40 planned participants, with an independent DSMB confirming the decision and reporting no related serious adverse events or discontinuations.
-
Trial Streamlining to Accelerate Development
The company plans to maintain the 300mg/2mL Q2W dose, remove the 600mg/4mL dose arm from Part B, and reduce total patient enrollment, potentially accelerating the trial and BLA filing.
-
Strong Financial Runway
Reported $514.4 million in cash, cash equivalents, and investments as of December 31, 2025, providing a projected cash runway into 2028.
Analysis
Dianthus Therapeutics announced an early "GO decision" in its Phase 3 CAPTIVATE trial for claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This significant milestone, achieved ahead of schedule and confirmed by an independent DSMB with a clean safety profile, indicates strong efficacy signals for their lead candidate. The company plans to streamline the trial by removing a dose arm and reducing patient enrollment, which could accelerate the path to a Biologics License Application (BLA) filing. This positive clinical de-risking event, combined with a robust cash position providing runway into 2028, significantly enhances the company's long-term prospects in a substantial market with high unmet medical needs. The stock is currently trading above its 52-week high, suggesting strong investor confidence which this news is likely to reinforce.
At the time of this filing, DNTH was trading at $75.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $13.37 to $65.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.